Edgewise Therapeutics, Inc.
EWTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$133,813 | -$100,163 | -$67,640 | -$42,813 |
| Dep. & Amort. | $2,290 | $1,732 | $538 | $272 |
| Deferred Tax | $0 | $0 | $0 | -$2,294 |
| Stock-Based Comp. | $24,712 | $17,560 | $10,924 | $4,404 |
| Change in WC | $10,328 | -$1,560 | $4,086 | $4,630 |
| Other Non-Cash | -$12,545 | -$9,517 | -$543 | $2,294 |
| Operating Cash Flow | -$109,028 | -$91,948 | -$52,635 | -$33,507 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,312 | -$5,745 | -$5,546 | -$668 |
| Net Acquisitions | $0 | $0 | $65 | $242 |
| Inv. Purchases | -$477,055 | -$255,866 | -$292,388 | -$288,203 |
| Inv. Sales/Matur. | $293,711 | $364,497 | $227,357 | $46,644 |
| Other Inv. Act. | $0 | $0 | -$65 | -$242 |
| Investing Cash Flow | -$184,656 | $102,886 | -$70,577 | -$242,227 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $239,147 | $52,618 | $129,165 | $186,148 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $10,106 | $548 | $474 | $236 |
| Financing Cash Flow | $249,253 | $53,166 | $129,639 | $186,384 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$44,431 | $64,104 | $6,427 | -$89,350 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $86,097 | $21,993 | $15,566 | $104,916 |
| End Cash | $41,666 | $86,097 | $21,993 | $15,566 |
| Free Cash Flow | -$110,340 | -$97,693 | -$58,181 | -$34,175 |